PRKCA and cancer: Also, we predicted that PRKCA, PRKCD, and PRKCE might be involved in improving the response of many cancers to PD-L1 blocking-dependent immunotherapies, but their effect on HLA-dependent therapies may run in line with their effect on the TILs aggregation.